Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) was the recipient of a large growth in short interest in August. As of August 31st, there was short interest totalling 3,811,277 shares, a growth of 5.2% from the August 15th total of 3,621,714 shares. Currently, 3.5% of the shares of the stock are short sold. Based on an average trading volume of 619,084 shares, the short-interest ratio is presently 6.2 days.
Shares of Actinium Pharmaceuticals stock traded up $0.04 during trading on Wednesday, reaching $0.66. 580,647 shares of the company’s stock were exchanged, compared to its average volume of 1,147,607. Actinium Pharmaceuticals has a 1-year low of $0.33 and a 1-year high of $0.85.
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last posted its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02.
ATNM has been the subject of several analyst reports. Zacks Investment Research raised Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, July 14th. B. Riley lifted their price objective on Actinium Pharmaceuticals from $2.75 to $3.00 and gave the company a “buy” rating in a report on Thursday, July 12th. Finally, Maxim Group reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Actinium Pharmaceuticals in a report on Tuesday, August 14th. Five research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average target price of $3.75.
Institutional investors have recently bought and sold shares of the company. Worth Venture Partners LLC acquired a new position in shares of Actinium Pharmaceuticals during the 1st quarter worth $140,000. Renaissance Technologies LLC raised its holdings in shares of Actinium Pharmaceuticals by 1,269.5% during the 2nd quarter. Renaissance Technologies LLC now owns 387,500 shares of the biotechnology company’s stock worth $248,000 after buying an additional 359,205 shares in the last quarter. Sio Capital Management LLC acquired a new position in shares of Actinium Pharmaceuticals during the 1st quarter worth $393,000. Sabby Management LLC acquired a new position in shares of Actinium Pharmaceuticals during the 1st quarter worth $729,000. Finally, Anson Funds Management LP acquired a new position in shares of Actinium Pharmaceuticals during the 1st quarter worth $1,502,000.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.
Featured Article: Average Daily Trade Volume – ADTV
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.